AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 Validated as Myasthenia Gravis Biomarkers: A Comparative Proteomic Study With MS, CIDP, and Controls
European Journal of Neurology · 2025-11 · 32 (11)
DOI: 10.1111/ene.70426 ↗At a glance
Multizentrische Studie in European Journal of Neurology, published online on 2025-11-14. Written by Amol K Bhandage and 8 co-authors. Institution: Department of Medical Sciences, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden. Major MEDLINE topics: Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, Multiple Sclerosis. Cited 4 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Familjen Erling-Perssons Stiftelse, Myasthenia Gravis Foundation of America, Deutsche Forschungsgemeinschaft.
Abstract (original language)
Background and Purpose Myasthenia gravis (MG) lacks disease‐specific biomarkers that can support monitoring of disease activity or guide treatment decisions. This study aimed to validate serum inflammatory proteins as MG‐specific biomarkers by comparing their specificity to controls and individuals with other autoimmune neurological disorders, including multiple sclerosis (MS) and chronic inflammatory demyelinating polyneuropathy (CIDP).
Methods
In this multicentre cross‐sectional study, serum from 200 acetylcholine receptor antibody seropositive (AChR+) MG patients, 192 matched controls, 93 MS patients, and 51 CIDP patients was analyzed using a 92‐plex inflammation panel (Olink PEA). Logistic regression, principal component analysis, and Boruta machine learning algorithms identified differentially expressed proteins. MG subgroups were defined by age at onset, disease severity, and immunosuppressive treatment.
Results
Fourteen proteins significantly distinguished MG from controls, including AXIN1 (OR: 0.24), IL7 (OR: 9.38), ST1A1 (OR:0.42), IL10 (OR:3.62), CASP‐8 (OR:1.61), and TNFSF14 (OR:0.50) (Bonferroni‐corrected p < 0.00135). AXIN1, ST1A1, STAMBP, CDCP1, and SIRT2 were specific for MG, separating it from MS and CIDP. Shared markers across disorders included IL6, IL8, STAMBP, and TNFSF14. A 15‐protein profile, including FGF‐23 and CXCL9, correlated with MG severity. Subgroup analyses revealed distinct protein patterns by age and treatment. TRANCE and CD6 were reduced in immunosuppressed patients, whereas EN‐RAGE, IL10, and TNFRSF9 varied in those receiving biologicals.
Conclusions
This study validates the MG‐specific serum proteomic biomarkers AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 and identifies signatures associated with severity, onset, and treatment. These findings support the use of blood‐based biomarkers for monitoring and stratification in MG clinical trials and care.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Medical Sciences, Clinical Neurophysiology, Uppsala University, Uppsala, Sweden.
- Department of Neurology With Experimental Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität Zu Berlin, Berlin, Germany.
- Neuroscience Clinical Research Center, Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt Universität Zu Berlin, Berlin, Germany.
- Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.
- Center for Stroke Research Berlin, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, Berlin, Germany.
- Clinical Neurophysiology, Uppsala University Hospital, Uppsala, Sweden.
ORCID profiles: Amol K Bhandage, Sarah Hoffmann, Carla Dusemund, Frauke Stascheit, Yu-Fang Huang, Niclas Eriksson, Katja Gabrysch, Andreas Meisel, Anna Rostedt Punga
Funding
- Familjen Erling-Perssons Stiftelse
- Myasthenia Gravis Foundation of America
- Deutsche Forschungsgemeinschaft
Cite
APA
Bhandage, A. K., Hoffmann, S., Dusemund, C., Stascheit, F., Huang, Y. F., Eriksson, N., Gabrysch, K., Meisel, A., & Punga, A. R. (2025). AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 Validated as Myasthenia Gravis Biomarkers: A Comparative Proteomic Study With MS, CIDP, and Controls. European Journal of Neurology, 32(11). https://doi.org/10.1111/ene.70426
Vancouver
Bhandage AK, Hoffmann S, Dusemund C, Stascheit F, Huang YF, Eriksson N, et al. AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 Validated as Myasthenia Gravis Biomarkers: A Comparative Proteomic Study With MS, CIDP, and Controls. European Journal of Neurology. 2025;32(11). doi:10.1111/ene.70426
BibTeX
@article{Bhandage2025,
author = {Bhandage, Amol K and Hoffmann, Sarah and Dusemund, Carla and Stascheit, Frauke and Huang, Yu-Fang and Eriksson, Niclas and Gabrysch, Katja and Meisel, Andreas and Punga, Anna Rostedt},
title = {AXIN1, STAMBP, ST1A1, CDCP1, and SIRT2 Validated as Myasthenia Gravis Biomarkers: A Comparative Proteomic Study With MS, CIDP, and Controls},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {11},
doi = {10.1111/ene.70426}
}
EUVIMED